HWPC(SH:688799) Ge Long Hui A P P·2026-02-13 08:10Core Viewpoint - Warner Pharmaceuticals (688799.SH) reported a preliminary performance summary for the fiscal year 2025, indicating a revenue increase and significant growth in net profit, driven by various product sales and investment income [1] Financial Performance - The company achieved an operating revenue of 1.516 billion yuan, representing a year-on-year growth of 7.26% [1] - The net profit attributable to the parent company was 241 million yuan, showing a year-on-year increase of 46.95% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 130 million yuan, reflecting a year-on-year decline of 6.01% [1] Asset and Equity Growth - At the end of the reporting period, the total assets of the company reached 3.053 billion yuan, marking a year-on-year growth of 24.11% [1] - The equity attributable to the parent company was 2.046 billion yuan, which is a year-on-year increase of 13.44% [1] Revenue Drivers - The growth in operating revenue was primarily due to increased sales of formulation products, raw materials, intermediates, and technical service income [1] - The increase in net profit attributable to the parent company was mainly influenced by investment income [1] - The decline in net profit after deducting non-recurring gains and losses was attributed to the accrual of equity incentive expenses; excluding this impact, the adjusted net profit was 182 million yuan, which is a 31.57% increase compared to the same period last year [1]